FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, where X1, X2, X11, X12, R1, R3, R5, R5', R6 and R7 are defined in the claims as USP1 inhibitors. Also disclosed are pharmaceutical compositions containing compounds of formula I, and a method of inhibiting protein USP1.
EFFECT: compounds of formula I can be used to treat a disorder responsive to inhibition of USP1 proteins, particularly for treating cancer.
13 cl, 7 tbl, 224 ex
Title | Year | Author | Number |
---|---|---|---|
BICYCLIC LACTAMS AND METHODS OF USE THEREOF | 2016 |
|
RU2827714C1 |
SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
COMPOSITION OF TETRAHYDROQUINOLINES AS BROMODOMAIN BET MODIFYING AGENTS | 2014 |
|
RU2727169C2 |
TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
SUBSTITUTED 2H-PYRAZOLE DERIVATIVE | 2016 |
|
RU2722363C2 |
SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
TRICYCLIC COMPOUNDS PROVIDING DESTRUCTION OF IKAROS PROTEIN AND AIOLOS PROTEIN | 2020 |
|
RU2833608C2 |
SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | 2011 |
|
RU2652638C2 |
Authors
Dates
2025-01-15—Published
2019-12-19—Filed